Home › NDC Lookup › RxCUI directory › RxCUI 2283509

Cenobamate 150 MG Oral Tablet [Xcopri] — RxCUI 2283509

RxNorm drug concept · Semantic branded drug
RxCUI 2283509 Semantic branded drug · SBD ● Current RxNorm concept 11 FDA products 12 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2283509
Official nameCenobamate 150 MG Oral Tablet [Xcopri]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asXcopri 150 MG Oral Tablet
FDA products mapped11
Package NDCs mapped12
Reported Medicaid activity (SDUD)139,992 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cenobamate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Xcopri is a prescription seizure medication approved for adults who have partial-onset seizures — the kind of seizure that starts in one specific area of the brain. Your doctor may...
  • The slow, step-by-step dose increase is actually a critical safety measure, not just a formality. When Xcopri was started too quickly in some patients, a rare but serious reaction...
  • Why does my doctor have to start me at such a low dose? Can't we just go faster?
  • The most common ones are drowsiness, dizziness, fatigue, double vision, and headache. These tend to be more noticeable when you first start or when your dose is being increased. Be...
📖 Read our full Cenobamate guide →

🕸️ Concept Web — How Cenobamate 150 MG Oral Tablet [Xcopri] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cenobamate 150 MG Oral Tablet [Xcopri] RxCUI 2283509

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Cenobamate 2265690
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Xcopri 2265696
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cenobamate Oral Tablet 2265694
    • Cenobamate Oral Product 2265692
    • Cenobamate Pill 2265693
    • Cenobamate Oral Tablet [Xcopri] 2265698
    • Xcopri Oral Product 2265699
    • Xcopri Pill 2265700
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 6

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

11 products · 12 package NDCs
12 package NDCs map to RxCUI 2283509 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71699-0025-30 30 TABLET, FILM COATED in 1 BOTTLE (71699-025-30) Xcopri SK Life Science, Inc. 2024-04-06
71699-0050-30 30 TABLET, FILM COATED in 1 BOTTLE (71699-050-30) Xcopri SK Life Science, Inc. 2021-04-30
71699-0050-99 30 TABLET, FILM COATED in 1 BOTTLE (71699-050-99) Xcopri SK Life Science, Inc. 2021-04-30
71699-0100-30 30 TABLET, FILM COATED in 1 BOTTLE (71699-100-30) Xcopri SK Life Science, Inc. 2020-03-12
71699-0103-56 1 KIT in 1 CARTON (71699-103-56) * 1 TABLET, FILM COATED i... Xcopri Maintenance Pack SK Life Science, Inc. 2020-03-12
71699-0104-56 1 KIT in 1 CARTON (71699-104-56) * 1 TABLET, FILM COATED i... Xcopri Maintenance Pack SK Life Science, Inc. 2021-04-30
71699-0150-30 30 TABLET, FILM COATED in 1 BOTTLE (71699-150-30) Xcopri SK Life Science, Inc. 2020-03-12
71699-0200-30 30 TABLET, FILM COATED in 1 BOTTLE (71699-200-30) Xcopri SK Life Science, Inc. 2020-03-12
71699-0201-28 1 KIT in 1 CARTON (71699-201-28) * 1 TABLET in 1 BLISTER P... Xcopri Titration Pack SK Life Science, Inc. 2020-03-12
71699-0202-28 1 KIT in 1 CARTON (71699-202-28) * 1 TABLET, FILM COATED i... Xcopri Titration Pack SK Life Science, Inc. 2020-03-12
71699-0203-28 1 KIT in 1 CARTON (71699-203-28) * 1 TABLET, FILM COATED i... Xcopri Titration Pack SK Life Science, Inc. 2020-03-12
71699-0204-14 14 BLISTER PACK in 1 CARTON (71699-204-14) / 1 TABLET in 1... Xcopri SK Life Science, Inc. 2026-02-01
Observed labelers: SK Life Science, Inc. (12) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.